Technical Analysis for CLDX - Celldex Therapeutics, Inc.

Grade Last Price % Change Price Change
grade F 3.11 -0.32% -0.01
CLDX closed down 0.32 percent on Monday, May 20, 2019, on 61 percent of normal volume. The bears made the stock sink to a new 52-week low. Due to the stock's strong downtrend, it may remain oversold for a while. So, if you're looking for a reason to buy, don't put too much weight on it being oversold.

Trend Table & Recent Signals
ADX Long-Term Intermediate-Term Short-Term
Strong Down Down Down
See historical CLDX trend table...

Date Alert Name Type % Chg
Narrow Range Bar Range Contraction 0.00%
Doji - Bullish? Reversal 0.00%
New 52 Week Low Weakness 0.00%
Wide Bands Range Expansion 0.00%
Down 3 Days in a Row Weakness 0.00%
Oversold Stochastic Weakness 0.00%
Narrow Range Bar Range Contraction -0.32%
Stochastic Reached Oversold Weakness -0.32%
Oversold Stochastic Weakness -0.32%
Narrow Range Bar Range Contraction -4.60%

Older signals for CLDX ...

Free Daily (Stock) Chart Reading

Let us help you stay on top of your investments. We will alert you to important technical developments on your portfolio & watchlist.
Configure default chart indicators
Basic chart:

Profile
Celldex Therapeutics, Inc., a biopharmaceutical company, focuses on the development, manufacture, and commercialization of novel therapeutics for human health care primarily in the United States. The company has a pipeline of drug candidates in development for the treatment of cancer and other difficult-to-treat diseases based on its antibody focused precision targeted immunotherapy platform. Its lead drug candidates include rindopepimut (CDX-110), a targeted immunotherapeutic in a pivotal Phase III study for the treatment of front-line glioblastoma and a Phase II study for the treatment of recurrent glioblastoma; and CDX-011, an antibody-drug conjugate, which completed a randomized Phase IIb study for the treatment of advanced breast cancer. The company also has various earlier stage candidates in clinical development, such as CDX-1135, a molecule that inhibits a part of the immune system called the complement system; CDX-1127, a therapeutic fully human monoclonal antibody for cancer indications that is in Phase I study in patients with selected malignant solid tumors or hematologic cancers; CDX-301, an immune cell mobilizing agent and dendritic cell growth factor, which completed Phase I study in healthy subjects; and CDX-1401, an antibody-targeted technology program for cancer indications that completed Phase I study in combination with toll-like receptor agonists poly-ICLC. Its preclinical product candidate includes CDX-014, a human monoclonal antibody-drug conjugate that targets TIM-1, a molecule that is expressed on renal and ovarian cancers with minimal expression in normal tissues. It has research collaboration and license agreements with Medarex, Inc.; Rockefeller University; Duke University Brain Tumor Cancer Center; Ludwig Institute for Cancer Research; Thomas Jefferson University; University of Southampton; Amgen Inc.; Amgen Fremont; and Seattle Genetics, Inc. Celldex Therapeutics, Inc. was founded in 1983 and is headquartered in Needham, Massachusetts.
Medicine Biotechnology Biopharmaceutical Cancer Clinical Medicine Immunology Treatment Of Cancer Immunotherapy Immune System Monoclonal Antibodies Cancer Treatments Antibody Drug Conjugates Seattle Genetics Cancer Research Amgen Advanced Breast Cancer Hematologic Cancers Recurrent Glioblastoma Targeted Immunotherapy Treatment Of Advanced Breast Cancer
Is CLDX a Buy, Sell or Hold?
Indicator Bull Case Neutral / Hold Bear Case
50 DMA
200 DMA
ADX Trend
Oversold / Overbought
Relative Strength
Summary: Counts: 0 bullish, 4 bearish and 1 neutral indicators. You may wish to incorporate that into your trading strategies.
Indicators
Indicator Value
52 Week High 174.2625
52 Week Low 3.02
Average Volume 455,973
200-Day Moving Average 56.3029
50-Day Moving Average 4.2182
20-Day Moving Average 3.571
10-Day Moving Average 3.356
Average True Range 0.4171
ADX 42.21
+DI 13.6565
-DI 34.3211
Chandelier Exit (Long, 3 ATRs ) 2.8287
Chandelier Exit (Short, 3 ATRs ) 4.2713
Upper Bollinger Band 4.1382
Lower Bollinger Band 3.0038
Percent B (%b) 0.09
BandWidth 31.767012
MACD Line -0.7238
MACD Signal Line -0.9004
MACD Histogram 0.1767
Fundamentals Value
Market Cap 399.15 Million
Num Shares 128 Million
EPS -1.09
Price-to-Earnings (P/E) Ratio -2.85
Price-to-Sales 32.43
Price-to-Book 1.32
PEG Ratio 0.00
Dividend 0.00
Dividend Yield 0.00%
Pivot Point Level Traditional / Classic Fibonacci Demark Woodie Camarilla
Resistance 4 (R4) 3.32
Resistance 3 (R3) 3.31 3.24 3.29
Resistance 2 (R2) 3.24 3.18 3.24 3.27
Resistance 1 (R1) 3.17 3.15 3.18 3.18 3.26
Pivot Point 3.10 3.10 3.10 3.10 3.10
Support 1 (S1) 3.03 3.04 3.04 3.04 2.96
Support 2 (S2) 2.96 3.01 2.96 2.95
Support 3 (S3) 2.89 2.96 2.94
Support 4 (S4) 2.90